ALK’s Peanut Allergy Tablet Shows Strong Phase 2 Efficacy, Clearing Path to Phase 3
Event summary
- ALK’s phase 2 ALLIANCE trial demonstrated statistically significant efficacy in treating peanut allergy after just 6 months of maintenance treatment.
- Highest dose of the peanut tablet showed 49% of patients tolerating 300 mg peanut protein vs. 18% in placebo (p<0.001).
- No treatment-related anaphylaxis or serious adverse events reported; trial included 150 patients aged 4-65 years.
- Phase 3 development expected to begin late 2026 pending regulatory feedback on trial design.
The big picture
ALK’s successful phase 2 trial positions it as a leader in developing sublingual immunotherapy for peanut allergy, a condition affecting over 10 million people in Europe, the USA, and Canada. The trial’s strong efficacy and safety data suggest a potential breakthrough in treating a severe, life-threatening allergy with limited current treatment options. The rapid progression to phase 3 development indicates ALK’s confidence in the peanut tablet’s commercial potential.
What we're watching
- Regulatory Pathway
- Whether ALK can secure regulatory approval for its peanut tablet given the strong phase 2 data.
- Market Potential
- The pace at which ALK can commercialize the peanut tablet if phase 3 trials succeed.
- Competitive Landscape
- How ALK’s peanut tablet compares to existing and emerging treatments for peanut allergy.
Related topics